Document Detail

Vulnerable plaque: definition, detection, treatment, and future implications.
MedLine Citation:
PMID:  15727727     Owner:  NLM     Status:  MEDLINE    
Atherosclerosis continues to account for significant morbidity and mortality in most of the world. The major proportion of atherosclerosis mortality is related to atherosclerotic coronary artery disease, yet there still is not an optimal method for making the diagnosis of vulnerable plaque in vivo. The search for such an undefined method, along with studies on amelioration of currently available technology, gains special significance when the association between the qualitative definition of lesions in an individual and cardiovascular risks are considered. We, therefore, start by defining the critical lesion of coronary atherosclerosis and review the advantages and potential for clinical use of various methods to detect the vulnerable plaque and comment on possible future implications in this field.
Kerem Ozer; Mehmet Cilingiroglu
Related Documents :
17367657 - Impact of metabolic syndrome on tissue characteristics of angiographically mild to mode...
6686877 - Social instability and coronary artery atherosclerosis in cynomolgus monkeys.
9117137 - Lipid-lowering trials in the primary and secondary prevention of coronary heart disease...
12948037 - Can serum lipid and crp levels predict the "severity" of aortic valve stenosis?
20514557 - Open-loop dynamic and static characteristics of the carotid sinus baroreflex in rats wi...
3579417 - Dynamic left ventricular outflow tract obstruction when the anterior leaflet is retaine...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Current atherosclerosis reports     Volume:  7     ISSN:  1523-3804     ISO Abbreviation:  Curr Atheroscler Rep     Publication Date:  2005 Mar 
Date Detail:
Created Date:  2005-02-24     Completed Date:  2005-06-02     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  100897685     Medline TA:  Curr Atheroscler Rep     Country:  United States    
Other Details:
Languages:  eng     Pagination:  121-6     Citation Subset:  IM    
Department of Medicine, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adrenergic beta-Antagonists / therapeutic use
Angioplasty, Transluminal, Percutaneous Coronary
Angiotensin-Converting Enzyme Inhibitors / therapeutic use
Anticholesteremic Agents / therapeutic use
Coronary Artery Disease* / complications,  diagnosis,  therapy
Coronary Thrombosis* / diagnosis,  etiology,  therapy
Coronary Vessels / pathology
Diagnostic Imaging / methods
Diagnostic Techniques, Cardiovascular
Endothelium, Vascular / pathology
Platelet Aggregation Inhibitors / therapeutic use
Reg. No./Substance:
0/Adrenergic beta-Antagonists; 0/Angiotensin-Converting Enzyme Inhibitors; 0/Anticholesteremic Agents; 0/Platelet Aggregation Inhibitors

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Thiazolidinediones and cardiovascular disease.
Next Document:  The use of myeloperoxidase as a risk marker for atherosclerosis.